PG
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Cytochrome P450 phenotyping using the Geneva cocktail improves metabolic capacity prediction in a hospitalized patient population | British journal of clinical pharmacology | 2025 | 41 | 0 | |||
| Improving Understanding of Fexofenadine Pharmacokinetics to Assess Pgp Phenotypic Activity in Older Adult Patients Using Population Pharmacokinetic Modeling | Clinical pharmacokinetics | 2025 | 62 | 79 | |||
| Virtual twin approach using physiologically based pharmacokinetic modelling in hospitalized patients treated with apixaban or rivaroxaban | British journal of clinical pharmacology | 2025 | 75 | 0 | |||
| Multi-omics correlates of insulin resistance and circadian parameters mapped directly from human serum | European journal of neuroscience | 2024 | 84 | 162 | |||
| Apixaban and rivaroxaban's physiologically-based pharmacokinetic model validation in hospitalized patients: A first step for larger use of a priori modeling approach at bed side | CPT: pharmacometrics & systems pharmacology | 2023 | 142 | 362 | |||
| Population pharmacokinetics of apixaban in a real-life hospitalized population from the OptimAT study | CPT: pharmacometrics & systems pharmacology | 2023 | 132 | 316 | |||
| Dexamethasone exposure in normal-weight and obese hospitalized COVID-19 patients: An observational exploratory trial | Clinical and translational science | 2022 | 153 | 133 | |||
| Impact of the Genotype and Phenotype of CYP3A and P-gp on the Apixaban and Rivaroxaban Exposure in a Real-World Setting | Journal of personalized medicine | 2022 | 224 | 311 | |||
| Liquid Biopsy for Patient Characterization in Cardiovascular Disease: Verification against Markers of Cytochrome P450 and P-Glycoprotein Activities | Clinical pharmacology and therapeutics | 2022 | 179 | 370 | |||
| Ether lipids, sphingolipids and toxic 1-deoxyceramides as hallmarks for lean and obese type 2 diabetic patients | Acta Physiologica | 2021 | 399 | 3 |
